Joel Lewis Sells 7,829 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock

19 Dec 2025, 23:10 by Mitch Edgeman · The Markets Daily

Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) CEO Joel Lewis sold 7,829 shares of Galectin Therapeutics stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $7.06, for a total transaction of $55,272.74. Following the sale, the chief executive officer directly owned 832,592 shares of the company’s stock, valued at $5,878,099.52. This represents a 0.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Joel Lewis also recently made the following trade(s):

On Wednesday, November 5th, Joel Lewis sold 200 shares of Galectin Therapeutics stock. The stock was sold at an average price of $6.00, for a total value of $1,200.00.
On Tuesday, November 4th, Joel Lewis sold 14,420 shares of Galectin Therapeutics stock. The stock was sold at an average price of $6.07, for a total value of $87,529.40.
On Monday, November 3rd, Joel Lewis sold 1,300 shares of Galectin Therapeutics stock. The shares were sold at an average price of $6.01, for a total value of $7,813.00.

Galectin Therapeutics Stock Performance

GALT traded down $1.78 during midday trading on Friday, reaching $4.38. 4,104,617 shares of the company were exchanged, compared to its average volume of 417,051. The stock has a market capitalization of $282.38 million, a P/E ratio of -7.42 and a beta of 0.95. Galectin Therapeutics Inc. has a one year low of $0.73 and a one year high of $7.13. The stock’s 50-day simple moving average is $5.57 and its 200 day simple moving average is $4.15.

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, research analysts anticipate that Galectin Therapeutics Inc. will post -0.73 earnings per share for the current year.

Analyst Ratings Changes

GALT has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Galectin Therapeutics in a report on Wednesday, October 8th. HC Wainwright lifted their target price on Galectin Therapeutics from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Wednesday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $11.00.

View Our Latest Research Report on GALT

Key Headlines Impacting Galectin Therapeutics

Here are the key news stories impacting Galectin Therapeutics this week:

Positive Sentiment: FDA written response aligns with the company on the proposed patient population for a registration trial of belapectin and the company will pursue a follow‑up Type C meeting to finalize trial design; management says new biomarker data will be presented. This reduces some regulatory uncertainty for the lead program. Galectin Therapeutics Provides Regulatory Update
Positive Sentiment: Galectin secured a $10M unsecured, convertible line of credit from its chairman and extended maturities on related notes, which management says funds operations into at least March 2027 — a near‑term liquidity buffer while belapectin development continues. Regulatory update & financing
Neutral Sentiment: Technically, the stock recently crossed above its 200‑day moving average — a bullish technical sign for some traders, but not a fundamental change. Shares Cross Above 200-Day Moving Average
Negative Sentiment: Significant insider selling: multiple insiders (CEO Joel Lewis, Director Harold H. Shlevin, CMO Khurram Jamil) sold large blocks of stock on Dec. 16–17 at prices in the $6.66–$7.06 range — and a major shareholder (Fund L.P. 10X) also sold ~30,681 shares. The concentrated selling likely pressured the share price despite the regulatory/financing news. Insider Selling: Galectin Therapeutics
Negative Sentiment: While HC Wainwright maintained a Buy and raised its price target to $11 (from $6), analyst optimism can be slower to offset immediate selling pressure from insiders and short‑term traders. HC Wainwright maintains Buy, raises target

Institutional Investors Weigh In On Galectin Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. HighTower Advisors LLC increased its holdings in Galectin Therapeutics by 244.1% during the 1st quarter. HighTower Advisors LLC now owns 77,375 shares of the company’s stock worth $94,000 after purchasing an additional 54,889 shares in the last quarter. Wealthspire Advisors LLC boosted its position in shares of Galectin Therapeutics by 20.4% during the second quarter. Wealthspire Advisors LLC now owns 479,518 shares of the company’s stock worth $1,012,000 after buying an additional 81,144 shares during the period. Truist Financial Corp bought a new position in shares of Galectin Therapeutics during the second quarter worth about $143,000. Geneos Wealth Management Inc. grew its holdings in shares of Galectin Therapeutics by 8.8% during the first quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company’s stock worth $516,000 after buying an additional 34,300 shares in the last quarter. Finally, Stratos Wealth Partners LTD. raised its position in Galectin Therapeutics by 17.8% in the 2nd quarter. Stratos Wealth Partners LTD. now owns 60,750 shares of the company’s stock valued at $128,000 after buying an additional 9,200 shares during the last quarter. 11.68% of the stock is owned by institutional investors.

Galectin Therapeutics Company Profile

(Get Free Report)

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.